T1	Participants 78 114	advanced non-small cell lung cancer:
T2	Participants 273 351	patients with locally advanced or metastatic non-small cell lung cancer (NSCLC
T3	Participants 784 830	105 (GA arm, 51; PG arm, 54) eligible patients
